The BIONIKK trial is the first prospective biomarker-driven randomized trial in metastatic clear cell renal cell carcinoma. This trial demonstrates the feasibility of using a transcriptomic biomarker that reflects intrinsic disease biology to optimize treatment efficacy and shows that all patients might not require combination treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Demasure, S. et al. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 61, 22–29 (2022).
Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706–720 (2019).
Vano, Y.-A. et al. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00128-0 (2022).
Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015).
Verbiest, A. et al. Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors. Clin. Genitourin. Cancer 17, e981–e994 (2019).
Roussel, E. et al. Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials. Clin. Genitourin. Cancer https://doi.org/10.1016/j.clgc.2021.07.005 (2021).
Roussel, E. et al. Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncol. 60, 1499–1506 (2021).
Singla, N. et al. Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight 5, e134564 (2020).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.B. has provided input on the ccrcc molecular grouping for the BIONIKK trial. E.R. and M.A. declare no competing interests.
Rights and permissions
About this article
Cite this article
Roussel, E., Beuselinck, B. & Albersen, M. Tailoring treatment in metastatic renal cell carcinoma. Nat Rev Urol 19, 455–456 (2022). https://doi.org/10.1038/s41585-022-00615-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-022-00615-z
